miR-122, a paradigm for the role of microRNAs in the liver

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Inflammasomes in liver diseases
Volume 61, Issue 4, Pages (October 2014)
Volume 50, Issue 4, Pages (April 2009)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Clinician's Guide to Hepatitis C
Hepatic CD141+IFNλ+ DC subset: One against all?
Reactive oxygen species in the normal and acutely injured liver
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C
Hepatitis C-associated B-cell non-Hodgkin lymphomas
Immigration and viral hepatitis
The Coming of Age for Piwi Proteins
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
Hepatitis C virus entry and glucocorticosteroids
Mutation Altering the miR-184 Seed Region Causes Familial Keratoconus with Cataract  Anne E. Hughes, Declan T. Bradley, Malcolm Campbell, Judith Lechner,
Living donor liver transplantation: is the hype over?
Volume 57, Issue 6, Pages (December 2012)
Mechanisms of HBV-related hepatocarcinogenesis
Volume 69, Issue 2, Pages (August 2018)
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Biology of the immunomodulatory molecule HLA-G in human liver diseases
Volume 61, Issue 2, Pages (August 2014)
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
Hepatitis C core protein – The “core” of immune deception?
Student Presentation Template: Expectations for Completion of Explore Evolution Project By: Krizia Cabrera Purdue University.
by , Christine G. Elsik, Ross L. Tellam, and Kim C. Worley
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
Biomarkers of liver cell death
A dive into the complexity of type I interferon antiviral functions
RNAi – A powerful tool to unravel hepatitis C virus–host interactions within the infectious life cycle  Joachim Lupberger, Laurent Brino, Thomas F. Baumert 
Inhibition of mammalian target of rapamycin: Two goals with one shot?
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Ribavirin ante portas: Uptake transporters into hepatocytes dissected
Exome Sequencing Identifies SLCO2A1 Mutations as a Cause of Primary Hypertrophic Osteoarthropathy  Zhenlin Zhang, Weibo Xia, Jinwei He, Zeng Zhang, Yaohua.
Genomic risk of hepatitis C-related hepatocellular carcinoma
MicroRNAs: Hidden in the Genome
Autophagy in the liver Journal of Hepatology
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
EASL Clinical Practice Guidelines: Wilson’s disease
Volume 61, Issue 1, Pages S45-S57 (November 2014)
Volume 50, Issue 2, Pages (February 2009)
Stephen Locarnini, Angelos Hatzakis, Ding-Shinn Chen, Anna Lok 
Marcel Klingenberg, Akiko Matsuda, Sven Diederichs, Tushar Patel 
Volume 50, Issue 4, Pages (April 2009)
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Gyongyi Szabo, Peter Sarnow, Shashi Bala  Journal of Hepatology 
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
Fei Xiao, Jane A. McKeating, Thomas F. Baumert  Journal of Hepatology 
miR-122 – A key factor and therapeutic target in liver disease
Immigration and viral hepatitis
Kornelius Schulze, Jean-Charles Nault, Augusto Villanueva 
HCV targeting of patients with cirrhosis
Volume 66, Issue 1, Pages (January 2017)
Volume 63, Issue 1, Pages (July 2015)
The use of hemospray in portal hypertensive bleeding; a case series
Epigenetic modifications as new targets for liver disease therapies
HCV animal models and liver disease
Pathogenesis of cholestatic hepatitis C
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
Chimeric mouse model of hepatitis B virus infection
Eva Gottwein, Bryan R. Cullen  Cell Host & Microbe 
Genetics of hepatocellular carcinoma: The next generation
Volume 70, Issue 5, Pages (May 2019)
Philippe Metz, Antje Reuter, Silke Bender, Ralf Bartenschlager 
Volume 53, Issue 4, Pages (October 2010)
Presentation transcript:

miR-122, a paradigm for the role of microRNAs in the liver Muriel Girard, Emmanuel Jacquemin, Arnold Munnich, Stanislas Lyonnet, Alexandra Henrion-Caude  Journal of Hepatology  Volume 48, Issue 4, Pages 648-656 (April 2008) DOI: 10.1016/j.jhep.2008.01.019 Copyright © 2008 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Phylogenetic tree of miR-122 sequences. For analysis, we selected 10 representative miR-122 RNA precursors amongst 10 species. Sanger accession numbers are indicated for each sequence. The phylogenetic tree is based on a multi-gene analysis using MEGA v4.0 with Neighbor-Joining method. Distance scale is shown below. Full species names corresponding to the miRNAs are as follows: ssc, Sus scrofa; bta, Bos taurus; mmu, Mus musculus; hsa, Homo sapiens; gga, Gallus gallus; mdo, Monodelphis domestica; tni, Tetraodon nigroviridis; fru, Fugu rubripes; xtr, Xenopus tropicalis; rno, Rattus novergicus; dre, Danio rerio. Despite the short sequences, the major clades are well separated in this phylogenetic tree. Most mammalian vertebrates cluster well in the upper part of the tree. Journal of Hepatology 2008 48, 648-656DOI: (10.1016/j.jhep.2008.01.019) Copyright © 2008 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Complexity of miRNA-mediated host–pathogen interaction. Genes within the host genome as well as the viral genome encode miRNAs and mRNAs. In the liver, known examples of the host–pathogen interaction involve host miRNA in their regulation of either cellular (arrow 1) or viral mRNAs (arrow 4), and viral miRNA in their regulation of cellular (arrow 2) or viral mRNAs (arrow 3). In turn, four situations arise in which host-encoded miRNAs can target host mRNAs (referred to as 1, e.g., miR-122 regulates cytoprotective enzyme heme-oxygenase 1 [29]), or virus-encoded miRNAs may bind to host mRNAs (referred to as 2, e.g., EBV vmiRNAs putatively binds Bcl-2 mRNA [40]), or virus-encoded miRNAs may bind to viral mRNAs (referred to as 3, e.g., HBV vmiRNA possibly targeting HBV genome [43]), or host-encoded miRNAs can target viral mRNAs (referred to as 4, e.g., interferon-beta induced miRNAs can bind sequences in the HCV genome [63]). Journal of Hepatology 2008 48, 648-656DOI: (10.1016/j.jhep.2008.01.019) Copyright © 2008 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2008 48, 648-656DOI: (10. 1016/j. jhep. 2008. 01 Copyright © 2008 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2008 48, 648-656DOI: (10. 1016/j. jhep. 2008. 01 Copyright © 2008 European Association for the Study of the Liver Terms and Conditions